Coronavirus / COVID

Monica McArthur, MD, PhD, discusses why to-be-authorized COVID-19 vaccine doses for children may not be tiered for patient risk as they were for adults.

New late-breaking data illuminate the specific efficacy of the combination monoclonal antibodies.

A new study from IDWeek showed most observed children previously infected with SARS-CoV-2 retained antibodies over 6 months.

The COVID-19 pandemic led people to take hygiene and sanitation more seriously, causing a decrease in C difficile infections.

After an initial hospitalization for COVID-19, some patients may have specific risk factors that increase their likelihood of readmittance.

Major predictors of response were CD4+ count, suppressed viral load, and whether the participant received the Moderna or Pfizer mRNA vaccine.

The Arkansas Health Department’s research showed that, as with the rest of the population, Delta is severely infectious for children.

Investigators examined asymptomatic infection and the duration of viral shedding in symptomatic breakthrough infections in a phase 3 study with the AZD1222 COVID-19 vaccine.

Unpublished, interim phase 3 data show an approximate 50% reduction in hospitalizations and deaths versus placebo. Merck is expediting FDA application for the antiviral drug.

In the primary efficacy analysis, the risk of developing symptomatic COVID 19 was reduced by 77% with AZD7442.

The study author of the late-breaking IDWeek findings discusses what the new data mean for using the antiviral to reduce COVID-19 burden.

An expert explains the science of vaccine- and infection-induced immunity, and how it informs the timeline of COVID-19 outbreaks this year.

In newly hospitalized hypoxic patients with COVID-19, the monoclonal antibody significantly improved survival without invasive mechanical ventilation compared with placebo and available treatments, according to phase 3 trial results.

A new study breaks down the risk prediction of death or hospitalization related to COVID-19 in adults following their vaccination.

“Compared to the pre-COVID period, the odds ratio for CVD encounters was nearly doubled in each post-COVID period from 31 to 90 days post onset,” Brian Agan, MD, deputy science director and HIV research director of the Infectious Disease Clinical Research Program at USU/HJF and presenting author, told Contagion®.

Research suggests studies should adjust their cohort comparison group to account for demographics most represented by people living with HIV.

The companies will be seeking emergency authorization for a lighter-dose mRNA vaccine for children aged 5 to <12 years old.

Data finds low risk for anaphylaxis, myocarditis, and other potential complications.

Extended findings from blinded mRNA-1273 vaccine pivotal trial include efficacy across subgroups, including elderly and with coexisting conditions.

Only about 60% of Americans have immunity, a number too low to protect the country through “herd immunity,” according to a new report.

A CDC examination of a Delta outbreak in a Texas prison showed unvaccinated persons have higher attack rates, hospitalizations, and deaths, but vaccinated persons can still contract and spread the virus.

In a departure from the independent APIC advisors, CDC Director Rochelle Walensky, MD, has decided to recommend boosters for people in high-risk occupations.

The Advisory Committee on Immunization Practices posed a series of 4 questions related to a potential third shot of the Pfizer-BioNTech COVID-19 vaccine in various populations.

A third dose booster vaccination given to persons 60 years of age or over in Israel was confirmed to lower their rate of COVID-19 infection compared to a 2-dose regimen.

New research shows COVID-19 mortality risk to be more nuanced than previous studies.